The global albumin (as excipient) market is experiencing steady growth, driven by increasing demand from pharmaceutical and biotechnology industries. Albumin plays a critical role in drug formulation, vaccine production, and drug delivery systems due to its unique biochemical properties and compatibility with biological systems.

According to industry analysis, the global albumin (as excipient) market was valued at US$ 0.81 Bn in 2021 and is projected to grow at a CAGR of 6.3% from 2022 to 2031, reaching more than US$ 1.7 Bn by the end of 2031.

Albumin is widely recognized as a multifunctional protein used as a stabilizer, carrier molecule, and protective agent in pharmaceutical formulations. The protein’s ability to bind a wide range of molecules, maintain osmotic pressure, and prevent aggregation of therapeutic proteins makes it an ideal excipient for vaccines, biologics, and advanced drug delivery systems.

With the rapid expansion of biologics manufacturing and increased research activities in regenerative medicine and vaccine development, the demand for albumin-based excipients is expected to grow significantly in the coming years.

Gain a preview of important insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3984

Key Drivers of Market Growth

Several factors are contributing to the growth of the global albumin (as excipient) market.

Increasing Use in Drug Development and Vaccine Production

Albumin is extensively used in drug delivery systems and vaccine formulations due to its stabilizing properties. The protein protects active pharmaceutical ingredients from degradation and ensures thermal stability during manufacturing and storage.

During the COVID-19 pandemic, albumin gained attention for its use in vaccine development. It helps prevent surface adsorption and protects therapeutic proteins from shear stress during processing.

As pharmaceutical companies continue to develop biologics, monoclonal antibodies, and protein-based therapies, the demand for high-quality excipients such as albumin is rising.

Rising Number of Pharmaceutical and Biotechnology Companies

The rapid growth of the pharmaceutical and biotechnology sector globally is creating strong demand for excipients used in drug formulation and development.

Albumin’s multifunctional nature allows it to serve multiple purposes, including stabilizing proteins, acting as a carrier molecule, and enhancing drug solubility. As drug pipelines expand across therapeutic areas such as oncology, autoimmune diseases, and metabolic disorders, the use of albumin as a critical formulation component continues to increase.

Growing Prevalence of Chronic Diseases

The increasing incidence of chronic conditions such as cancer, rheumatoid arthritis, diabetes, and hepatitis is another major factor driving market expansion. Albumin-based drug delivery systems are commonly used to improve the effectiveness of treatments for these diseases.

Pharmaceutical companies are also exploring albumin-drug conjugates and albumin nanoparticles for targeted drug delivery, further strengthening market demand.

Key Players and Industry Leaders

The global albumin (as excipient) market is relatively consolidated, with a small number of companies dominating the industry through technological expertise and extensive product portfolios.

Leading companies operating in the market include:

• Albumedix Ltd.
• Biotest AG
• CSL Behring
• Grifols, S.A.
• HiMedia Laboratories
• InVitria
• Octapharma AG
• RayBiotech, Inc.
• Sigma-Aldrich Co.
• Takeda Pharmaceutical Company Limited

These companies are investing heavily in research and development to develop innovative albumin-based technologies for pharmaceutical applications. Strategic partnerships, mergers, and product launches are also helping companies strengthen their market presence.

Recent Developments

Several strategic initiatives and product launches have shaped the global albumin (as excipient) market in recent years.

In July 2021, Grifols, S.A. partnered with ImmunoTek Bio Centers to expand plasma collection centers in the United States, aiming to increase plasma supply for albumin production.

In July 2020, Grifols announced the acquisition of GC Pharma Group’s plasma fractionation facility in South Korea for approximately US$ 460 Mn, strengthening its manufacturing capabilities and global distribution network.

In May 2020, Bio Products Laboratory introduced ALBUMINEX 5% and ALBUMINEX 25%, human albumin solutions used in the treatment of hypovolemia, hypoalbuminemia, ascites, and acute respiratory distress syndrome.

These developments highlight the industry’s focus on expanding production capacity and improving therapeutic applications of albumin.

New Opportunities and Challenges

While the albumin (as excipient) market presents significant growth opportunities, several challenges remain.

Opportunities

The growing demand for recombinant albumin is creating new opportunities for manufacturers. Regulatory agencies are encouraging the use of non-animal derived materials in biologics manufacturing to minimize contamination risks.

Recombinant albumin offers several advantages over traditional plasma-derived albumin, including higher purity, improved safety, and consistent quality. As pharmaceutical companies adopt recombinant technologies, the demand for recombinant albumin is expected to increase rapidly.

Challenges

One of the major challenges in the market is the high cost associated with albumin production and purification. Plasma-derived albumin requires complex processing and strict regulatory compliance.

Additionally, maintaining a stable supply of plasma-derived raw materials can be difficult, especially during global health emergencies or supply chain disruptions.

Market Trends & Innovations

The albumin (as excipient) market is evolving rapidly with advancements in biotechnology and drug delivery systems.

One of the most prominent trends is the development of albumin-based drug delivery platforms. Albumin nanoparticles and albumin-drug conjugates are being explored to improve drug targeting and reduce side effects.

Another key trend is the use of albumin in cell culture media and regenerative medicine applications. Albumin is widely used as a stabilizer in laboratory research and in vitro fertilization procedures.

The shift toward recombinant albumin technology is also gaining momentum, as pharmaceutical companies aim to eliminate animal-derived components from therapeutic products.

Future Outlook

The future of the global albumin (as excipient) market looks promising as pharmaceutical innovation continues to accelerate worldwide.

The increasing use of biologics, vaccines, and personalized medicines is expected to drive long-term demand for advanced excipients such as albumin. In addition, ongoing research in nanotechnology and drug delivery systems will expand the scope of albumin applications.

Emerging markets in Asia Pacific, particularly China and India, are anticipated to play a major role in market expansion due to increasing healthcare investment and rising pharmaceutical manufacturing activities.

Overall, the albumin (as excipient) market is poised for sustainable growth through 2031, supported by technological innovation and expanding applications in life sciences.

Market Segmentation

By Product Type

• Human Serum Albumin
• Recombinant Albumin

By Application

• Drug Formulation
• Drug Delivery
• Vaccines
• Medical Device Coating
• Culture Medium & Stabilizer
• Diagnostics
• In Vitro Fertilization

By End-User

• Pharmaceutical & Biotechnology Industry
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Buy this Premium Research Report to gain valuable industry intelligence – https://www.transparencymarketresearch.com/checkout.php?rep_id=3984&ltype=S

Key Trends for the Future

Several trends are expected to shape the future of the albumin (as excipient) market:

• Growing adoption of recombinant albumin technology
• Rising demand for albumin-based drug delivery systems
• Expansion of biologics and biosimilar drug development
• Increased investments in pharmaceutical research and development
• Rapid growth of the biotechnology sector in emerging economies

These trends indicate that albumin will continue to play a vital role in pharmaceutical innovation and advanced therapeutics.

Important FAQs

How large was the global albumin (as excipient) market in 2021?

The global albumin (as excipient) market was valued at US$ 0.81 Bn in 2021.

What is the projected market size by 2031?

The market is expected to reach more than US$ 1.7 Bn by the end of 2031.

What is the expected CAGR during the forecast period?

The market is projected to grow at a CAGR of 6.3% from 2022 to 2031.

Which region dominates the albumin (as excipient) market?

North America currently holds the largest share due to strong pharmaceutical research activities and advanced healthcare infrastructure.

Which industries are the primary users of albumin as an excipient?

The pharmaceutical and biotechnology industries are the primary end-users, utilizing albumin in drug formulation, vaccine production, and drug delivery systems.

More Related Reports-

Nanotechnology Drug Delivery Market: https://www.transparencymarketresearch.com/nanotechnology-drug-delivery-market.html

Water for Injection Market: https://www.transparencymarketresearch.com/water-for-injection-market.html

Allergy Treatment Market: https://www.transparencymarketresearch.com/allergy-treatment-market.html

Bioengineered Protein Drugs Market: https://www.transparencymarketresearch.com/bioengineered-proteins-drugs-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact Us

Transparency Market Research Inc.

CORPORATE HEADQUARTER DOWNTOWN,

1000 N. West Street,

Suite 1200, Wilmington, Delaware 19801 USA

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453